December 14, 2022
CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort
CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in...
Read More
November 22, 2022
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate...
Read More
September 26, 2022
CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US
CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced...
Read More
September 10, 2022
CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination
CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for...
Read More
September 5, 2022
CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress
CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15...
Read More